Know Cancer

forgot password

A Phase I/II Study of Intravenous AMD3100 Added to a Mobilization Regimen of G-CSF to Increase the Number of Autologous Peripheral Blood Stem Cells Collected From Patients With Lymphoma

Phase 1/Phase 2
18 Years
75 Years
Open (Enrolling)
Lymphoma, Non-Hodgkin, Hodgkin Disease

Thank you

Trial Information

A Phase I/II Study of Intravenous AMD3100 Added to a Mobilization Regimen of G-CSF to Increase the Number of Autologous Peripheral Blood Stem Cells Collected From Patients With Lymphoma

Autologous stem cell transplantation (ASCT) is indicated for patients with non-Hodgkin
lymphoma (NHL) or Hodgkin lymphoma (HL) who have primary progressive disease or who relapse
after a chemotherapy-induced complete remission. For these patients, as for other patients
undergoing autologous transplantation, the number of CD34+ cells collected is a reliable
predictor of neutrophil and platelet (PLT) engraftment after transplantation.

AMD3100 (plerixafor) is a promising new mobilizing agent that has demonstrated efficacy in
patients with NHL, HL, and multiple myeloma (MM). Although efficacious, the subcutaneous
dosing of AMD3100 requires that patients receive the drug in the evening prior to apheresis,
which can present logistical problems. Intravenous dosing of AMD3100 may result in a faster
rise in peripheral CD34+ cell count, so that the drug can be administered the same day as
apheresis. Intravenous dosing may also increase the peak CD34+ cell count, improving the
number of CD34+ cells collected via apheresis.

This Phase I/II study will evaluate the safety and efficacy of intravenous AMD3100 added to
the standard G-CSF mobilization regimen of patients undergoing autologous stem cell
transplantation for Hodgkin and non-Hodgkin lymphomas.

Inclusion Criteria:

- Age 18 to 75 years

- Diagnosis of HL or NHL eligible for autologous transplantation

- 30 days since last cycle of chemotherapy

- ECOG performance status of 0 or 1

- The patient has recovered from all acute toxic effects of prior chemotherapy

- WBC >3.0 X 109/l

- Absolute PMN count >1.5 X 109/l

- PLT count >100 X 109/l

- Serum creatinine ≤ 2.2 mg/dl

- AST (SGOT), ALT (SGPT) and total bilirubin < 2X upper limit of normal (ULN)

- Left ventricle ejection fraction > 45% (by ECHO or MUGA scan)

- FEV1 > 60% of predicted or DLCO > 45% of predicted

- Negative for HIV on standard transplant workup

- Signed informed consent

- Are surgically or biologically sterile or willing to practice acceptable birth
control, as follows:

- Females of child bearing potential must agree to abstain from sexual activity or
to use a medically approved contraceptive measure/regimen during and for 3
months after the treatment period. Women of child bearing potential must have a
negative serum or urine pregnancy test at the time of enrollment. Acceptable
methods of birth control include oral contraceptive, intrauterine device (IUD),
transdermal/implanted or injected contraceptives and abstinence.

- Males must agree to abstain from sexual activity or agree to utilize a medically
approved contraception method during and for 3 months after the treatment period

Exclusion Criteria:

- A co-morbid condition which, in the view of the investigator, renders the patient at
high risk for treatment complications

- Patients who have failed previous collections

- A residual acute medical condition resulting from prior chemotherapy

- Acute infection

- Fever (temp >38C/100.4F) on the day of start of treatment

- Positive pregnancy test in female patients

- Lactating females

- Patients of child bearing potential unwilling to implement adequate birth control

- Patients whose actual body weight exceeds 150% of their ideal body weight

- History of ventricular arrhythmias

- Patients who previously received experimental therapy within 4 weeks of enrolling in
this study or who are currently enrolled in another experimental study during the
mobilization phase

- Patients who have deterioration of their clinical status or laboratory parameters
between the time of enrollment and transplantation such that they no longer meet
entry criteria may be removed from study at the discretion of the treating physician,
principal investigator, or sponsor

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated dose of IV AMD3100 + G-CSF in mobilization of peripheral blood stem cell in patients with lymphoma

Outcome Time Frame:

7 days from first dose of IV AMD3100

Safety Issue:


Principal Investigator

Amanda F. Cashen, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Washington Univerisity


United States: Food and Drug Administration

Study ID:

08-0897 / 201105349



Start Date:

November 2008

Completion Date:

September 2013

Related Keywords:

  • Lymphoma, Non-Hodgkin
  • Hodgkin Disease
  • Plerixafor
  • Lymphoma
  • Hematopoietic Stem Cell Mobilization
  • Transplantation, Autologous
  • Receptors, CXCR4
  • Hodgkin Disease
  • Lymphoma
  • Lymphoma, Non-Hodgkin



Washington UniversitySt. Louis, Missouri  63110